About half of adults with long COVID saw sustained symptom improvement within three years of infection, but the outlook depended heavily on which symptoms they had, according to a study published Nov. 3 in Annals of Internal Medicine. Roughly 60% of people whose illness centered on lost or changed smell and taste improved, compared with fewer than 1 in 5 of those whose symptoms spread across multiple body systems.

The findings come from the RECOVER-Adult study, funded by the National Institutes of Health, and are among the longest prospective answers yet to a question many patients ask: does long COVID go away? For some, the data offer real hope. For others — especially those with the most complex illness — the results point to a long road and an urgent need for treatment trials.

That split matters for households weighing work, school, caregiving, and disability decisions. A patient whose main symptom is a dulled sense of smell faces a very different three-year outlook than one living with fatigue, heart palpitations, dizziness, and digestive problems at once.

Inside the Three-Year Numbers

The researchers followed 1,019 adults who still had likely long COVID 12 months after their initial infection, according to an American College of Physicians release. Symptoms were tracked for up to three years after infection.

By two years, 36.2% had sustained symptom improvement. By three years, that rose to 50.1%. At the three-year mark, 56.4% had substantial symptom reductions with good quality of life, and 26.9% reached complete remission, meaning they reported none of the tracked symptoms at that time.

The team measured symptoms with the Long COVID Research Index, a 0-to-30 score covering 11 symptoms including fatigue, brain fog, dizziness, palpitations, cough, shortness of breath, and changes in smell or taste, according to Contagion Live. Participants counted as improved when their score stayed below the long COVID threshold for two consecutive visits.

Symptom Patterns Separate Fast and Slow Improvers

The study grouped patients by their dominant symptom pattern. Adjusted estimates showed improvement by three years for 59.6% of the smell-or-taste group, 54.6% of the chronic cough group, and 48.5% of the brain fog group. Patients in the palpitations group and the multisystem group did worse.

The multisystem group fared the poorest, with fewer than 1 in 5 improving within three years, Live Science reported. Other patterns also emerged. Adults under 46 improved more often than older participants, and people infected during the Omicron period improved more often than those infected with earlier variants. Men and women improved at similar rates.

Harrison Reeder, a biostatistician at Massachusetts General Hospital and the study's corresponding author, said the multisystem group "might be a group where an effective intervention can make a bigger difference." He told Live Science he deliberately avoided calling participants "recovered," because symptoms can fluctuate and patient advocates raised concerns about implying permanence.

Carmen Scheibenbogen, an immunologist at Charité University Medicine Berlin who was not involved in the study, told Live Science that the course in at least a major subgroup resembles myalgic encephalomyelitis/chronic fatigue syndrome, a condition that can follow many kinds of infection.

Reading the Hopeful Headline Carefully

The 50% figure is a modeled cumulative probability from a time-to-event analysis, not a simple headcount of people who got better. The authors also said the study was not designed to determine what causes some people to improve faster than others.

Outside experts raised questions about the scoring system itself. Ziyad Al-Aly, a clinical epidemiologist at the VA St. Louis Health Care System, told the Japan Times that the index gives substantial weight to smell and taste loss and chronic cough. Those symptoms are common after COVID-19 but are not central to the chronic multisystem illness he associates with long COVID. Nisreen Alwan of the University of Southampton noted that the index has not yet been independently validated in other populations.

The study also did not track whether people who improved later relapsed, according to Live Science. That leaves open whether some improvements will hold beyond three years.

Practical Guidance for Patients and Families

For people with long COVID, the study offers context, not a personal prognosis. Patients whose symptoms are mostly smell, taste, or cough can take some encouragement from the data. Those with fatigue that worsens after exertion, heart rhythm changes, dizziness, or symptoms across several systems should plan for a longer course and keep working with a clinician who tracks their symptoms over time.

Families should watch for warning signs that need prompt medical attention, including chest pain, fainting, severe shortness of breath, or sudden worsening of symptoms. These are not typical long COVID patterns to wait out.

Patients may also want to keep a symptom diary, which can support conversations with doctors, employers, and disability programs. The NIH's RECOVER initiative posts research updates and information on clinical trials.

Treatment Trials Are the Next Test

The authors and the journal release said the findings point to a need for placebo-controlled studies of possible treatments. The multisystem group, with the lowest odds of improving on its own, may stand to gain the most from an effective therapy.

The bottom line is that long COVID does improve for many people, and about half of those in this study saw sustained gains within three years. But the hopeful average hides a hard reality for patients with multisystem illness, most of whom were still symptomatic at three years. The next answers will have to come from treatment trials.

What Readers Want to Know

What did the long COVID study find? About half of 1,019 adults with long COVID had sustained symptom improvement within three years of infection, and about 27% reached complete remission.

Which long COVID patients improved most often? People whose symptoms centered on smell or taste changes improved most often, at about 60%, followed by those with chronic cough.

Who is least likely to improve? Patients with multisystem symptoms. Fewer than 1 in 5 in that group improved within three years.

Does "improved" mean cured? No. The researchers avoided the word "recovered," and the study did not track whether symptoms later returned.

Who funded the research? The study used data from the RECOVER-Adult cohort, funded by the National Institutes of Health.

What should people with long COVID do now? Keep working with a clinician, track symptoms, and seek urgent care for chest pain, fainting, or severe breathing problems. The RECOVER initiative lists clinical trial information.